93 related articles for article (PubMed ID: 17363616)
1. 5-AZA-2'-deoxycytidine in cancer immunotherapy: a mouse to man story.
Coral S; Sigalotti L; Covre A; Nicolay HJ; Natali PG; Maio M
Cancer Res; 2007 Mar; 67(6):2900-1; author reply 2901-2. PubMed ID: 17363616
[No Abstract] [Full Text] [Related]
2. Phenotypic and functional changes of human melanoma xenografts induced by DNA hypomethylation: immunotherapeutic implications.
Coral S; Sigalotti L; Colizzi F; Spessotto A; Nardi G; Cortini E; Pezzani L; Fratta E; Fonsatti E; Di Giacomo AM; Nicotra MR; Natali PG; Altomonte M; Maio M
J Cell Physiol; 2006 Apr; 207(1):58-66. PubMed ID: 16252259
[TBL] [Abstract][Full Text] [Related]
3. 5-aza-2'-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications.
Coral S; Sigalotti L; Altomonte M; Engelsberg A; Colizzi F; Cattarossi I; Maraskovsky E; Jager E; Seliger B; Maio M
Clin Cancer Res; 2002 Aug; 8(8):2690-5. PubMed ID: 12171902
[TBL] [Abstract][Full Text] [Related]
4. De novo induction of a cancer/testis antigen by 5-aza-2'-deoxycytidine augments adoptive immunotherapy in a murine tumor model.
Guo ZS; Hong JA; Irvine KR; Chen GA; Spiess PJ; Liu Y; Zeng G; Wunderlich JR; Nguyen DM; Restifo NP; Schrump DS
Cancer Res; 2006 Jan; 66(2):1105-13. PubMed ID: 16424047
[TBL] [Abstract][Full Text] [Related]
5. Chlorin e6-mediated photodynamic effect diminishes therapeutic potential of 5-aza-2'-deoxycytidine-based whole-tumour-cell vaccine in mice bearing squamous cell carcinoma SCCVII.
Marczynska J; Banas M; Guzik K; Koltun M; Majewski P; Cichy J; Krzykawska-Serda M; Makarska A; Kwitniewski M
J Photochem Photobiol B; 2015 Dec; 153():455-62. PubMed ID: 26569454
[TBL] [Abstract][Full Text] [Related]
6. The Levels of H11/HspB8 DNA methylation in human melanoma tissues and xenografts are a critical molecular marker for 5-Aza-2'-deoxycytidine therapy.
Smith CC; Li B; Liu J; Lee KS; Aurelian L
Cancer Invest; 2011 Jul; 29(6):383-95. PubMed ID: 21649464
[TBL] [Abstract][Full Text] [Related]
7. Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo.
Sanchez-Perez L; Kottke T; Diaz RM; Ahmed A; Thompson J; Chong H; Melcher A; Holmen S; Daniels G; Vile RG
Cancer Res; 2005 Mar; 65(5):2009-17. PubMed ID: 15753401
[TBL] [Abstract][Full Text] [Related]
8. Limited gene activation in tumor and normal epithelial cells treated with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine.
Karpf AR; Lasek AW; Ririe TO; Hanks AN; Grossman D; Jones DA
Mol Pharmacol; 2004 Jan; 65(1):18-27. PubMed ID: 14722233
[TBL] [Abstract][Full Text] [Related]
9. The DNA demethylating agent 5-aza-2'-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells.
Almstedt M; Blagitko-Dorfs N; Duque-Afonso J; Karbach J; Pfeifer D; Jäger E; Lübbert M
Leuk Res; 2010 Jul; 34(7):899-905. PubMed ID: 20381863
[TBL] [Abstract][Full Text] [Related]
10. Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2'-deoxycytidine.
Sigalotti L; Fratta E; Coral S; Tanzarella S; Danielli R; Colizzi F; Fonsatti E; Traversari C; Altomonte M; Maio M
Cancer Res; 2004 Dec; 64(24):9167-71. PubMed ID: 15604288
[TBL] [Abstract][Full Text] [Related]
11. Demethylating agent 5-aza-2'-deoxycytidine enhances expression of TNFRI and promotes TNF-mediated apoptosis in vitro and in vivo.
Kaminski R; Kozar K; Niderla J; Grzela T; Wilczynski G; Skierski JS; Koronkiewicz M; Jakobisiak M; Golab J
Oncol Rep; 2004 Sep; 12(3):509-16. PubMed ID: 15289829
[TBL] [Abstract][Full Text] [Related]
12. Interleukin 12-based immunotherapy improves the antitumor effectiveness of a low-dose 5-Aza-2'-deoxycitidine treatment in L1210 leukemia and B16F10 melanoma models in mice.
Kozar K; Kamiński R; Switaj T; Ołdak T; Machaj E; Wysocki PJ; Mackiewicz A; Lasek W; Jakóbisiak M; Gołab J
Clin Cancer Res; 2003 Aug; 9(8):3124-33. PubMed ID: 12912964
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic modulation enhances the therapeutic effect of anti-IL-13R(alpha)2 antibody in human mesothelioma xenografts.
Takenouchi M; Hirai S; Sakuragi N; Yagita H; Hamada H; Kato K
Clin Cancer Res; 2011 May; 17(9):2819-29. PubMed ID: 21357681
[TBL] [Abstract][Full Text] [Related]
14. Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2'-deoxycytidine in cutaneous melanoma: immunotherapeutic implications.
Fonsatti E; Nicolay HJ; Sigalotti L; Calabrò L; Pezzani L; Colizzi F; Altomonte M; Guidoboni M; Marincola FM; Maio M
Clin Cancer Res; 2007 Jun; 13(11):3333-8. PubMed ID: 17545540
[TBL] [Abstract][Full Text] [Related]
15. DNA Methylation Inhibitors in Cancer Therapy: The Immunity Dimension.
Licht JD
Cell; 2015 Aug; 162(5):938-9. PubMed ID: 26317460
[TBL] [Abstract][Full Text] [Related]
16. Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation.
Reu FJ; Bae SI; Cherkassky L; Leaman DW; Lindner D; Beaulieu N; MacLeod AR; Borden EC
J Clin Oncol; 2006 Aug; 24(23):3771-9. PubMed ID: 16801630
[TBL] [Abstract][Full Text] [Related]
17. [5-aza-2'-deoxycytidine-induced inhibition of CDH13 expression and its inhibitory effect on methylation status in human colon cancer cells in vitro and on growth of xenograft in nude mice].
Ren JZ; Huo JR
Zhonghua Zhong Liu Za Zhi; 2012 Jan; 34(1):6-10. PubMed ID: 22490847
[TBL] [Abstract][Full Text] [Related]
18. Inducible expression of a prostate cancer-testis antigen, SSX-2, following treatment with a DNA methylation inhibitor.
Dubovsky JA; McNeel DG
Prostate; 2007 Dec; 67(16):1781-90. PubMed ID: 17929270
[TBL] [Abstract][Full Text] [Related]
19. [Inhibitory effect of 5-Aza-2'-deoxycytidine on human nasopharyngeal carcinoma xenograft in nude mice].
Zhang S; Kong WJ; Wang YJ; Han YC; Zhang D
Ai Zheng; 2005 Oct; 24(10):1201-5. PubMed ID: 16219133
[TBL] [Abstract][Full Text] [Related]
20. Review of the clinical experience with 5-azacytidine and 5-aza-2'-deoxycytidine in solid tumors.
Aparicio A; Weber JS
Curr Opin Investig Drugs; 2002 Apr; 3(4):627-33. PubMed ID: 12090735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
